Hemastatx

Hemastatx is committed to bringing scientific innovation to patients with severe and underserved bleeding disorders, aiming to become a leader in hematology. Founded in 2025 as a spin-off from KU Leuven, Hemastatx builds on over a decade of pioneering research in hemostasis at the Laboratory for Thrombosis Research, led by Prof. dr. Karen Vanhoorelbeke. Our first lead program, HMX-001, is a proprietary monoclonal antibody designed to stop bleeding in patients with von Willebrand factor (VWF)-related disorders by targeting the underlying biological mechanism. The program is supported by a robust preclinical data package and broad patent protection. With headquarters in Switzerland and an R&D hub in Belgium, Hemastatx is strategically positioned within two of Europe’s leading biotech ecosystems.